Corticospinal tract degeneration associated with TDP-43 type C pathology and semantic dementia

Brain

Volumn 136, Issue 2, 2013, Pages 455-470

  Josephs, Keith A ^a   Whitwell, Jennifer L ^a   Murray, Melissa E ^b   Parisi, Joseph E ^a   Graff Radford, Neill R ^b   Knopman, David S ^a   Boeve, Bradley F ^a   Senjem, Matthew L ^a   Rademakers, Rosa ^b   Jack, Clifford R ^a   Petersen, Ronald C ^a   Dickson, Dennis W ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

corticospinal tract; MRI; right temporal lobe; semantic dementia; TDP 43 type C

Indexed keywords

MYELIN; PROGRANULIN; REPETITIVE DNA;

ADULT; AGED; AGNOSIA; AMYGDALOID NUCLEUS; ARTICLE; BEHAVIOR CHANGE; BRAIN STEM; CEREBELLUM; CONTROLLED STUDY; CORTICOSPINAL TRACT DEGENERATION; DEGENERATION; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FRONTOTEMPORAL DEMENTIA; FUSIFORM GYRUS; GENETIC SCREENING; HIPPOCAMPUS; HUMAN; INFERIOR TEMPORAL GYRUS; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MEDIAL LEMNISCUS; MEDULLARY PYRAMID; MICROGLIA; MIDDLE TEMPORAL GYRUS; MOTONEURON; MOTOR CORTEX; MOTOR CORTEX DEGENERATION; NERVE CELL DEGENERATION; NERVE FIBER; OLIVOPONTOCEREBELLAR TRACT; OPEN READING FRAME; PARAHIPPOCAMPAL GYRUS; PRIORITY JOURNAL; PROSOPAGNOSIA; SEMANTIC DEMENTIA; SUPERIOR TEMPORAL GYRUS; TDP 43 PROTEINOPATHY; TOPOGRAPHAGNOSIA; VASCULAR AMYLOIDOSIS;

EID: 84874320100     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws324     Document Type: Article

References (78)

1. Ahmed Z, Shaw G, Sharma VP, Yang C, McGowan E, Dickson DW. Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry. J Histochem Cytochem 2007; 55: 687-700.
2. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006; 351: 602-11.
3. Ashburner J, Friston KJ. Voxel-based morphometry-the methods. Neuroimage 2000; 11: 805-21.
4. Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005; 26: 839-51.
5. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006. 442.916-9
6. Beach TG, White CL, Hamilton RL, Duda JE, Iwatsubo T, Dickson DW, et al. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol 2008; 116: 277-88.
7. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
8. Burrell JR, Kiernan MC, Vucic S, Hodges JR. Motor neuron dysfunction in frontotemporal dementia. Brain 2011; 134: 2582-94.
9. Cairns NJ, Grossman M, Arnold SE, Burn DJ, Jaros E, Perry RH, et al. Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology 2004; 63: 1376-84.
10. Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ, et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 2007; 171: 227-40.
11. Chan D, Anderson V, Pijnenburg Y, Whitwell J, Barnes J, Scahill R, et al. The clinical profile of right temporal lobe atrophy. Brain 2009; 132: 1287-98.
12. Chan D, Fox NC, Scahill RI, Crum WR, Whitwell JL, Leschziner G, et al. Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Ann Neurol 2001; 49: 433-42.
13. Claassen DO, Parisi JE, Giannini C, Boeve BF, Dickson DW, Josephs KA. Frontotemporal dementia mimicking dementia with Lewy bodies. Cogn Behav Neurol 2008; 21: 157-63.
14. Coon EA, Sorenson EJ, Whitwell JL, Knopman DS, Josephs KA. Predicting survival in frontotemporal dementia with motor neuron disease. Neurology 2011a; 76: 1886-93.
15. Coon EA, Whitwell JL, Parisi JE, Dickson DW, Josephs KA. Right temporal variant frontotemporal dementia with motor neuron disease. J Clin Neurosci 2011b; 19: 85-91.
16. Davies RR, Hodges JR, Kril JJ, Patterson K, Halliday GM, Xuereb JH. The pathological basis of semantic dementia. Brain 2005; 128: 1984-95.
17. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72: 245-56.
18. Dickson D, editor. Neurodegeneration: the molecular pathology of dementia and movement disorders. Basel: ISN Neuropath Press; 2003.
19. Elamin M, Phukan J, Bede P, Jordan N, Byrne S, Pender N, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology 2011; 76: 1263-9.
20. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
21. Galton CJ, Patterson K, Graham K, Lambon-Ralph MA, Williams G, Antoun N, et al. Differing patterns of temporal atrophy in Alzheimer's disease and semantic dementia. Neurology 2001; 57: 216-25.
22. Geser F, Martinez-Lage M, Robinson J, Uryu K, Neumann M, Brandmeir NJ, et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 2009; 66: 180-9.
23. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-52.
24. Godbolt AK, Josephs KA, Revesz T, Warrington EK, Lantos P, King A, et al. Sporadic and familial dementia with ubiquitin-positive tau-negative inclusions: clinical features of one histopathological abnormality underlying frontotemporal lobar degeneration. Arch Neurol 2005; 62: 1097-101.
25. Gorno-Tempini ML, Dronkers NF, Rankin KP, Ogar JM, Phengrasamy L, Rosen HJ, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004; 55: 335-46.
26. Grossman M, Wood EM, Moore P, Neumann M, Kwong L, Forman MS, et al. TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions. Arch Neurol 2007; 64: 1449-54.
27. Gwinn-Hardy K, Mehta ND, Farrer M, Maraganore D, Muenter M, Yen SH, et al. Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol 2000; 99: 663-72.
28. Hodges JR, Davies R, Xuereb J, Kril J, Halliday G. Survival in frontotemporal dementia. Neurology 2003; 61: 349-54.
29. Hodges JR, Mitchell J, Dawson K, Spillantini MG, Xuereb JH,McMonagle P, et al. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain 2010; 133: 300-6.
30. Hu WT, Seelaar H, Josephs KA, Knopman DS, Boeve BF, Sorenson EJ, et al. Survival profiles of patients with frontotemporal dementia and motor neuron disease. Arch Neurol 2009; 66: 1359-64.
31. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702-5.
32. Josephs KA. Frontotemporal dementia and related disorders: deciphering the enigma. Ann Neurol 2008; 64: 4-14.
33. Josephs KA, Ahmed Z, Katsuse O, Parisi JF, Boeve BF, Knopman DS, et al. Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol 2007a; 66: 142-51.
34. Josephs KA, Dickson DW. Frontotemporal lobar degeneration with upper motor neuron disease/primary lateral sclerosis. Neurology 2007b; 69: 1800-1.
35. Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, Mann DM, et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 2011; 122: 137-53.
36. Josephs KA, Holton JL, Rossor MN, Braendgaard H, Ozawa T, Fox NC, et al. Neurofilament inclusion body disease: a new proteinopathy? Brain 2003; 126: 2291-303.
37. Josephs KA, Holton JL, Rossor MN, Godbolt AK, Ozawa T, Strand K, et al. Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathol Appl Neurobiol 2004; 30: 369-73.
38. Josephs KA, Knopman DS, Whitwell JL, Boeve BF, Parisi JE, Petersen RC, et al. Survival in two variants of tau-negative frontotemporal lobar degeneration: FTLD-U vs FTLD-MND. Neurology 2005; 65: 645-7.
39. Josephs KA, Lin WL, Ahmed Z, Stroh DA, Graff-Radford NR, Dickson DW. Frontotemporal lobar degeneration with ubiquitinpositive, but TDP-43-negative inclusions. Acta Neuropathol 2008a; 116: 159-67.
40. Josephs KA, Parisi JE, Knopman DS, Boeve BF, Petersen RC, Dickson DW. Clinically undetected motor neuron disease in pathologically proven frontotemporal lobar degeneration with motor neuron disease. Arch Neurol 2006; 63: 506-12.
41. Josephs KA, Stroh A, Dugger B, Dickson DW. Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathol 2009; 118: 349-58.
42. Josephs KA, Whitwell JL, Vemuri P, Senjem ML, Boeve BF, Knopman DS, et al. The anatomic correlate of prosopagnosia in semantic dementia. Neurology 2008b; 71: 1628-33.
43. Jovicich J, Czanner S, Greve D, Haley E, van der Kouwe A, Gollub R, et al. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage 2006; 30: 436-43.
44. Kato S. Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences. Acta Neuropathol 2008; 115: 97-114.
45. Kim SH, Seo SW, Go SM, Suh MK, Chin J, Jeong JH, et al. Semantic dementia combined with motor neuron disease. J Clin Neurosci 2009; 16: 1683-5.
46. Knopman DS, Mastri AR, Frey WH II, Sung JH, Rustan T. Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia. Neurology 1990; 40: 251-6.
47. Kobayashi Z, Tsuchiya K, Arai T, Yokota O, Yoshida M, Shimomura Y, et al. Clinicopathological characteristics of FTLD-TDP showing corticospinal tract degeneration but lacking lower motor neuron loss. J Neurol Sci 2010; 298: 70-7.
48. Lillo P, Garcin B, Hornberger M, Bak TH, Hodges JR. Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. Arch Neurol 2010; 67: 826-30.
49. Lipton AM, White CL III, Bigio EH. Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration. Acta Neuropathol 2004; 108: 379-85.
50. Mackenzie IR, Baborie A, Pickering-Brown S, Du Plessis D, Jaros E, Perry RH, et al. Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol (Berl) 2006; 112: 539-49.
51. Mackenzie IR, Foti D, Woulfe J, Hurwitz TA. Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain 2008; 131: 1282-93.
52. Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011; 122: 111-3.
53. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 2009; 117: 15-18.
54. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-72.
55. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001; 58: 1803-9.
56. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-86.
57. Mummery CJ, Patterson K, Price CJ, Ashburner J, Frackowiak RS, Hodges JR. A voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory. Ann Neurol 2000; 47: 36-45.
58. Munoz DG, Neumann M, Kusaka H, Yokota O, Ishihara K, Terada S, et al. FUS pathology in basophilic inclusion body disease. Acta Neuropathol 2009; 118: 617-27.
59. Murray ME, DeJesus-Hernandez M, Rutherford NJ, Baker M, Duara R, Graff-Radford NR, et al. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol 2011; 122: 673-90.
60. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-54.
61. Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 2009; 132: 2922-31.
62. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130-3.
63. Rohrer JD, Geser F, Zhou J, Gennatas ED, Sidhu M, Trojanowski JQ, et al. TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology 2010; 75: 2204-11.
64. Rohrer JD, Lashley T, Schott JM, Warren JE, Mead S, Isaacs AM, et al. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain 2011; 134: 2565-81.
65. Sampathu DM, Neumann M, Kwong LK, Chou TT, Micsenyi M, Truax A, et al. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol 2006; 169: 1343-52.
66. Seeley WW, Bauer AM, Miller BL, Gorno-Tempini ML, Kramer JH, Weiner M, et al. The natural history of temporal variant frontotemporal dementia. Neurology 2005; 64: 1384-90.
67. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998; 17: 87-97.
68. Snowden J, Neary D, Mann D. Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol 2007; 114: 31-8.
69. Snowden JS, Rollinson S, Thompson JC, Harris JM, Stopford CL, Richardson AM, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 2012; 135: 693-708.
70. Snowden JS, Thompson JC, Neary D. Knowledge of famous faces and names in semantic dementia. Brain 2004; 127: 860-72.
71. Thompson SA, Patterson K, Hodges JR. Left/right asymmetry of atrophy in semantic dementia: behavioral-cognitive implications. Neurology 2003; 61: 1196-203.
72. Tsuchiya K, Murayama S, Mitani K, Oda T, Arima K, Mimura M, et al. Constant and severe involvement of Betz cells in corticobasal degeneration is not consistent with pyramidal signs: a clinicopathological study of ten autopsy cases. Acta Neuropathol 2005; 109: 353-66.
73. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15: 273-89.
74. Whitwell JL, Jack CR Jr, Parisi JE, Senjem ML, Knopman DS, Boeve BF, et al. Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration? Neurology 2010; 75: 2212-20.
75. Whitwell JL, Przybelski SA, Weigand SD, Ivnik RJ, Vemuri P, Gunter JL, et al. Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain 2009; 132: 2932-46.
76. Yokota O, Tsuchiya K, Itoh Y, Ishizu H, Akiyama H, Ikeda M, et al. Frontotemporal lobar degeneration with ubiquitin pathology: an autopsy case presenting with semantic dementia and upper motor neuron signs with a clinical course of 19 years. Acta Neuropathol 2006; 112: 739-49.
77. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 2001; 20: 45-57.
78. Zhang YJ, Xu YF, Cook C, Gendron TF, Roettges P, Link CD, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci USA 2009; 106: 7607-12.